Effects of ginkgo biloba on in vitro osteoblast cells and ovariectomized rat osteoclast cells
- First Online:
- 120 Downloads
Ginkgo biloba extract (GBE) has a selective estrogen receptor modulator (SERM)-like biphasic effect on estrogen, and could be a potential alternative to hormone replacement therapy (HRT). Here, we investigated whether GBE can ameliorate estrogen-depleted osteoporosis in in vitro osteoblast cells and in estrogen-deprived ovariectomized (OVX) rats, a classical animal model for postmenopausal osteoporosis. GBE (50–150 μg/mL) significantly increased ALP (Alkaline phosphatase) activity of osteoblast cells, indicating that GBE promotes osteoblast mineralization. OVX rats exposed to GBE (100 and 200 mg/kg/day, oral treatment), raloxifene (3 mg/kg/day, oral treatment) or estradiol (E2, 10 μg/kg/day, subcutaneous injection) decreased osteoclast resorptive activity compared with OVX rats. GBE and raloxifene did not increase uterine weight compared with OVX rats, while E2 and Sham control did, suggesting that GBE has no uterotrophic activity, which is a disadvantage of estrogen therapy. In OVX rats, GBE did not restore severe bone density loss induced by OVX, indicating that GBE may be insufficient as therapeutic material for severe osteoporosis. However, despite its no effects on bone density loss in OVX rats, GBE did stimulate osteoblast differentiation and antiosteoclastic activity in vitro. Therefore, GBE may have preventive potential on osteoporosis as do other phytoestrogens.
Key wordsGinkgo biloba extracts Osteoporosis Ovariectomized rat Osteoclast Osteoblast
Unable to display preview. Download preview PDF.
- Brayboy, J. R., Chen, X. W., Lee, Y. S., and Anderson, J. J. B., The protective effects of ginkgo biloba extract (EGb 761) against free radical damage to osteoblast-like bone cells (MC3T3-E1) and the proliferative effects of EGb 761 on these cells. Nutr. Res., 21, 1275–1285 (2001).CrossRefGoogle Scholar
- Faber, A., Bouvy, M. L., Loskamp, L., van de Berg, P. B., Egberts, T. C., and de Jong-van den Berg, L. T., Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study. Br. J. Clin. Pharmacol., 60, 641–647 (2005).PubMedCrossRefGoogle Scholar
- Greendale, G. A., Reboussin, B. A., Hogan, P., Barnabei, V. M., Shumaker, S., Johnson, S., and Barrett-Connor, E., Symptom relief and side effects of postmenopausal hormone: results from the postmenopausal estrogen/progestin interventions trial. Obstet. Gynecol., 92, 982–988 (1998).PubMedCrossRefGoogle Scholar
- Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H. L., Elliott, G., Kelley, M. J., Sarosi, I., Wang, L., Xia, X. Z., Elliott, R., Chiu, L., Black, T., Scully, S., Capparelli, C., Morony, S., Shimamoto, G., Bass, M. B., and Boyle, W. J., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA, 96, 3540–3545 (1999).PubMedCrossRefGoogle Scholar
- MWS, Million Women Study Collaborators, Breast cancer and hormonereplacement therapy in the Million Women Study. Lancet 362, 419–427 (2003).Google Scholar
- Pang, J. L., Ricupero, D. A., Huang, S., Fatma, N., Singh, D. P., Romero, J. R., and Chattopadhyay, N., Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. Biochem. Pharmacol., 71, 818–826 (2006).PubMedCrossRefGoogle Scholar
- Prouillet, C., Mazière, J. C., Mazière, C., Wattel, A., Brazier, M., and Kamel, S., Stimulatory effect of naturally occurring flavonols quercetin and kaempferol on alkaline phosphatase activity in MG-63 human osteoblasts through ERK and estrogen receptor pathway. Biochem. Pharmacol., 67, 1307–1313 (2004).PubMedCrossRefGoogle Scholar
- Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones, B. N., Assaf, A. R., Jackson, R. D., Kotchen, J. M., Wassertheil-Smoller, S., and Wactawski-Wende, J., WHIMS Investigators, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory study: a randomized controlled trial. JAMA, 289, 2654–2662 (2003).CrossRefGoogle Scholar